Currently, molecular targeted tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have been widely used to treat patients with EGFR-activating mutations in NSCLC and have significantly improved patient outcomes [5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.